Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    Oncology nurse education
    ELNEC Milestone Marks Transformation of EOL Care for Countless Patients With Cancer
    November 20, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Melanoma

    FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma

    On July 30, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

    August 03, 2020
    Antihistamines May Improve Survival From Malignant Melanoma
    Melanoma

    Antihistamines May Improve Survival From Malignant Melanoma

    Users of two common antihistamines—desloratadine and loratadine—have lower mortality rates from cutaneous malignant melanoma than patients who use other antihistamines, researchers reported in Allergy.

    July 29, 2020
    Spotlight on Melanoma
    Melanoma

    Melanoma Prevention, Screening, Treatment, and Survivorship Recommendations

    It is no coincidence that May is Melanoma Awareness Month. As Americans take to the great outdoors, they also must take caution to protect their skin and prevent melanoma.  

    May 18, 2020
    FDA Approves New Dosing Regimen for Pembrolizumab
    U.S. Food and Drug Administration (FDA)

    FDA Approves New Dosing Regimen for Pembrolizumab

    April 30, 2020
    Head and Neck Melanoma Increases 51% in Young People
    Research

    Head and Neck Melanoma Increases 51% in Young People

    Incidence of melanoma in the head and neck areas increased 51.1% from 1995 to 2014, according to findings from a study published in JAMA Otolaryngology.

    December 11, 2019
    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy
    Immunotherapy

    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy

    Two-year survival rates for patients with advanced melanoma increased quickly after the introduction of ipilimumab in 2011, according to an analysis published the journal Cancer.

    September 04, 2019
    Gut Microbiome Diversity May Improve Response to Melanoma Immunotherapy
    Research

    Gut Microbiome Diversity May Improve Response to Melanoma Immunotherapy

    A high-fiber diet leading to higher gut microbiome diversity may improve response to anti-PD-1 immunotherapy in patients with melanoma, according to the results of a new study presented at the 2019 American Association for Cancer Research Annual Meeting in Atlanta, GA. 

    May 15, 2019
    FDA Approves Pembrolizumab for Adjuvant Treatment of Melanoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Adjuvant Treatment of Melanoma

    On February 15, 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. 

    February 19, 2019
    Older Patients Respond Better to Checkpoint Inhibitors for Melanoma
    Melanoma

    Older Patients Respond Better to Checkpoint Inhibitors for Melanoma

    Patients aged 62 and older are more likely to respond to immune checkpoint inhibitors for melanoma, such as pembrolizumab, according to findings from a study published in Clinical Cancer Research. A follow-up study showed that it may be because of age-related changes in the immune cells in melanoma tumors.

    September 19, 2018
    What Does the “E” Mean in the National Cancer Institute’s “ABCDE” Tool for Recognizing Melanoma?
    Melanoma

    What Does the “E” Mean in the National Cancer Institute’s “ABCDE” Tool for Recognizing Melanoma?

    What does the “E” mean in the National Cancer Institute’s “ABCDE” tool for recognizing melanoma?

    A. Extension

    B. Evolution

    C. Equal

    D. Expand

    August 31, 2018
    Skin Bacteria May Protect Against Melanoma
    Melanoma

    Skin Bacteria May Protect Against Melanoma

    A strain of Staphylococcus epidermis that’s common on healthy human skin may be protective against some types of skin cancer, according to findings from a study published in Science Advances.

    June 13, 2018
    Small Steps Toward Sun Safety Can Make a Big Difference
    Cancer prevention

    Small Steps Toward Sun Safety Can Make a Big Difference

    I haven’t always been convinced of the importance of sun safety. In my younger years, I got more sunburns than I’d like to admit in an attempt to develop a tan. In college, I spent afternoons studying outside on a sunny quad with nothing more than shorts and a tank top for sun protection.

    May 21, 2018
    Stay Current on Evolving Therapies in Melanoma
    Advanced practice nursing (APN)

    Stay Current on Evolving Therapies in Melanoma

    After decades of no new treatment options for advanced melanoma, several drugs for unresectable stage III and IV disease and recurrent melanoma have been approved, including newer classes of drugs such as checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 drugs) and signal transduction inhibitors (BRAF, MEK, and KIT inhibitors). Advanced practice registered nurses (APRNs) must be familiar with these newer agents and classes of drugs, especially the mutations that guide their use.

    May 10, 2018
    drug holidays improve therapy for melanoma
    Research

    Drug Holidays May Improve Therapy for Treatment-Resistant Melanoma

    Taking an intentional drug holiday may improve patients’ response to reintroduction of treatment in drug-resistant melanoma, according to the results of a study published in Cancer Discovery.

    January 17, 2018
    Adverse Events From Immunotherapy
    Immunotherapy

    Manage Adverse Events From Immunotherapy and Targeted Therapy for Melanoma

    New targeted and immunotherapy drug approvals have offered improved survival and disease outcomes for patients with melanoma, but the new therapies are also associated with a range of adverse events (AEs) that differ from those associated with chemotherapy. Oncology nurses will need to shift their thinking to best manage those AEs.

    September 12, 2017
    Ultraviolet Safety and Skin Cancer Risk
    Safety

    Raise Awareness in July for Ultraviolet Safety and Skin Cancer Risk

    With summer in full swing, it’s the perfect time to head outdoors and enjoy the sunny weather. But are you protecting yourself from potential risks? The U.S. Department of Health and Human Services has named July as Ultraviolet (UV) Safety Month. The goal is to spread the word about how important it is to protect everyone’s skin from the harmful effects of UV rays. This presents a teaching opportunity for oncology nurses and their patients—not just during July but all year long.

    July 06, 2017
    Combination therapies
    Melanoma

    Combination Treatment Improves Survival for Advanced Melanoma

    A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting.

    June 21, 2017
    Seborrheic Keratosis
    Melanoma

    Dermascopic Clues Help Identify Seborrheic Keratosis-Like Melanoma

    Melanomas that resemble seborrheic keratosis (SK) can be challenging to diagnose correctly. SKs are often removed without being evaluated dermascopically or sent for pathologic analysis, risking the possibility of missing a diagnosis of SK-like melanoma. A new study published in JAMA Dermatology outlined the key dermascopic clues that clinicians can use to identify SK-like melanomas to prevent treatment delays and achieve the best patient outcomes.

    May 18, 2017
    Melanoma Awareness
    Melanoma

    Encourage Malignant Melanoma Awareness in May

    As Melanoma/Skin Cancer Detection and Prevention Month, May is the perfect time to encourage people to examine their skin and seek medical assistance if they recognize signs of a melanoma. Early detection and prompt treatment is associated with a much higher survival rate for skin cancer diagnoses.

    May 12, 2017
    Melanoma Survivors
    Melanoma

    10% of Melanoma Survivors Report Intentional Tanning

    A study published in Cancer Epidemiology, Biomarkers, and Prevention looking at the ultraviolet radiation exposure and sun protection behaviors among melanoma survivors found that many survivors have room for improvement.

    May 10, 2017
    Early-Stage Melanoma
    Melanoma

    Disease Symptoms Most Likely to Predict Recurrence of Early-Stage Melanoma

    Patients and healthcare providers are most likely to detect recurrence of early-stage melanoma based on symptom reports rather than routine imaging tests, according to the results of a study published in the Journal of the American College of Surgeons.

    April 26, 2017
    Cancer treatments

    Pembrolizumab Associated With Long-Term Survival in Advanced Melanoma

    A new study has shown that 40% of patients with previously treated advanced melanoma were alive at three years’ follow-up after initiating treatment with pembrolizumab. The results were presented at the 2016 American Society of Clinical Oncology annual meeting.
    August 09, 2016
    Immunotherapy

    What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma

    A number of different oncolytic immunotherapies are in development for advanced melanoma, one of which is talimogene laherparepvec, a genetically modified recombinant herpes simplex virus type 1.
    July 12, 2016
    Combination therapy

    FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma

    The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
    January 10, 2014
    Melanoma

    FDA Approves Dabrafenib for Unresectable or Metastatic Melanoma

    On May 29, 2013, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar™ capsule, GlaxoSmithKline), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    May 30, 2013
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲